Curis (NASDAQ:CRIS) Receives Buy Rating from HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $43.00 target price on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Curis to a “strong sell” rating in a report on Saturday, August 8th. Zacks Research cut shares of Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $43.00.

Curis Price Performance

Shares of Curis stock opened at $1.80 on Monday. The company has a market cap of $3.76 million, a PE ratio of -0.13 and a beta of 3.13. The business has a 50 day moving average price of $5.84 and a 200-day moving average price of $11.69. Curis has a 52 week low of $1.54 and a 52 week high of $39.00.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 4,169.81%. As a group, research analysts anticipate that Curis will post -33.29 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Cable Car Capital LP bought a new stake in Curis during the second quarter valued at approximately $696,000. Flputnam Investment Management Co. purchased a new stake in Curis during the second quarter valued at about $128,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Curis by 2,883,237.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Curis by 52.2% during the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 125,823 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after buying an additional 78,265 shares during the last quarter. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.